CBS's Dr. Celine Gounder warns the move bypasses FDA scientists and may look like approval to patients. CBS also found a weight-loss peptide for sale at a Brooklyn corner store.
Recap by typeshit. Full story at WKMG.
The peptide item sits among gene therapy, Neuralink and Medicare news. The Alliance for Safe Biologic Medicines has asked HHS to pause the policy, citing FDA scientists.
Maria David Patten alleges Novo hid NAION risks; her case joins the federal MDL before Judge Karen Marston in Pennsylvania, where bellwether trials are expected.
HHS now lets pharmacies compound BPC-157, TB-500 and four others, but BoxingInsider notes all six remain on WADA's banned list for licensed boxers.
Politico looks at the warning signs around Health Secretary Kennedy's move to let six peptides that lack FDA approval reach the US market.
Healio
Durrani tells Healio the move bypassed rulemaking and FDA scientists, and warns patients may wrongly read it as FDA approval while long-term data is missing.
In an eight-week study of six monkeys per group, the Activin E antibody shifted loss toward fat versus 77% on semaglutide alone. Human trials are planned for 2027.
Loading…